Niagen Bioscience (NAGE) Change in Accured Expenses (2011 - 2026)
Niagen Bioscience (NAGE) reported Change in Accured Expenses of -$101000.0 for Q1 2026, down 108.19% year-over-year from $1.2 million in Q1 2025, and down 110.54% quarter-over-quarter from $958000.0 in Q4 2025.
Niagen Bioscience (NAGE) Change in Accured Expenses (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 15 years of Change in Accured Expenses data on file, last reported at -$101000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$101000.0, down 108.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $507000.0 (down 65.44% YoY), and the FY2025 annual result was $1.8 million, up 52.65% from the prior year.
- Change in Accured Expenses retreated to -$101000.0 in Q1 2026 per NAGE's latest filing, from $958000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $1.6 million in Q1 2022 and troughed at -$1.8 million in Q2 2024.
- A 5-year average of $350470.6 and a median of $958000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses surged 1756.67% in 2023, then sank 247.27% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $581000.0 in 2022, then slumped by 48.36% to $300000.0 in 2023, then surged by 269.0% to $1.1 million in 2024, then slipped by 13.46% to $958000.0 in 2025, then slumped by 110.54% to -$101000.0 in 2026.
- Business Quant data shows NAGE's Change in Accured Expenses at -$101000.0 in Q1 2026, $958000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn | -101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101,000.00 |
| Mar 31, 2026 | -101,000.00 |
| Dec 31, 2025 | 958,000.00 |
| Dec 31, 2025 | 958,000.00 |
| Sep 30, 2025 | 1.32 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | -1.67 Mn |
| Jun 30, 2025 | -1.67 Mn |
| Mar 31, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.23 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 971,000.00 |
| Sep 30, 2024 | 971,000.00 |
| Jun 30, 2024 | -1.84 Mn |
| Jun 30, 2024 | -1.84 Mn |
| Mar 31, 2024 | 972,000.00 |
| Mar 31, 2024 | 972,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Dec 31, 2023 | 300,000.00 |